Literature DB >> 10885147

One hundred years of aspirin.

T J Rinsema.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10885147      PMCID： PMC1044183          DOI： 10.1017/s0025727300065728

Source DB:  PubMed          Journal:  Med Hist        ISSN： 0025-7273            Impact factor:   1.419


× No keyword cloud information.
  1 in total

1.  Aspirin in Germany: the pharmaceutical industry and the pharmaceutical profession.

Authors:  J R McTavish
Journal:  Pharm Hist       Date:  1987
  1 in total
  5 in total

1.  Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Authors:  Liqun Huang; Gerardo G Mackenzie; Yu Sun; Nengtai Ouyang; Gang Xie; Kvetoslava Vrankova; Despina Komninou; Basil Rigas
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

2.  Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.

Authors:  George Mattheolabakis; Ioannis Papayannis; Jennifer Yang; Brandon M Vaeth; Ruixue Wang; Jela Bandovic; Nengtai Ouyang; Basil Rigas; Gerardo G Mackenzie
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-02

3.  [From the plant to chemistry--the early history of "rheumatic medication"].

Authors:  H Kaiser
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

4.  Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.

Authors:  Liqun Huang; Chi C Wong; Ka W Cheng; Basil Rigas
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

5.  Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

Authors:  Liqun Huang; Chi C Wong; Gerardo G Mackenzie; Yu Sun; Ka Wing Cheng; Kvetoslava Vrankova; Ninche Alston; Nengtai Ouyang; Basil Rigas
Journal:  BMC Cancer       Date:  2014-02-28       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.